The London Digestive Disease Institute (LDDI) Site Management Organization is a growing, Canadian network purpose-built to support clinical trials in inflammatory bowel disease (IBD).

Recruitment into IBD trials has become the rate-limiting step for most sponsors. Biologic-naive patients especially are increasingly difficult to identify in traditional academic centers, where patients have typically already cycled through multiple advanced therapies. The LDDI SMO was designed specifically to address this gap.

Our Model

The LDDI SMO brings together a curated, geographically distributed network of high-quality Canadian community sites led by experienced clinicians with high-volume practices and direct access to large, predominantly biologic-naive patient populations. Each site operates independently but within a unified LDDI framework:

• Harmonized SOPs and quality systems across all sites in the network

• Centralized regulatory, project management, and contracting support to streamline rapid startup and execution

• Shared staffing resources and coordinator support to maintain consistent performance across the network

• Protocol-level mentorship from LDDI senior investigators on every study

• Continuous GCP and therapeutic-area training to develop sites to sponsor-ready standards on an accelerated timeline

Our Investigators

Our investigators are hand picked. They have large clinical practices and are being developed as principal investigators under the direct mentorship of the LDDI leadership team. This model ensures that every study conducted within the network benefits from senior trial oversight — combining the patient access of community practice with the execution discipline of an academic center. Our current network include:

• Niagara Gastroenterology & Specialists

• Brantford GI Research Group

What This Offers Sponsors:

As sponsors advance their IBD portfolio the LDDI SMO offers:

• Access to a large pool of biologic-naive and earlier-line IBD patients across multiple Canadian geographies

• A single point of contact for multi-site feasibility, activation, and execution in Canada

• Consistent data quality and operational standards across every site in the network

• Accelerated site activation through centralized regulatory and contracting support

The LDDI SMO is well positioned to be a meaningful partner to current and future IBD development programs. We would welcome the opportunity to introduce the LDDI SMO to your clinical operations and site engagement teams, and to explore how our network can support your IBD studies. For further information please contact hprins@lddi.ca